
1. brain dev. 2018 jun;40(6):473-479. doi: 10.1016/j.braindev.2018.02.005. epub 2018
mar 26.

anti-n-methyl-d-aspartate receptor encephalitis children: incidence and
experience hong kong.

ho ac(1), chan sh(2), chan e(3), wong ss(4), fung st(5), cherk sw(5), fung el(6),
ma kh(7), tsui kw(7), yau ek(8), wong vc(1).

author information: 
(1)department paediatrics adolescent medicine, queen mary hospital, the
university hong kong, hong kong.
(2)department paediatrics adolescent medicine, queen mary hospital, the
university hong kong, hong kong. electronic address: sophehs@hku.hk.
(3)division clinical immunology, department pathology clinical
biochemistry, queen mary hospital, hong kong.
(4)department paediatrics adolescent medicine, united christian hospital, 
hong kong.
(5)department paediatrics, kwong wah hospital, hong kong.
(6)department paediatrics, prince wales hospital, hong kong.
(7)department paediatrics adolescent medicine, alice ho miu ling
nethersole hospital, hong kong.
(8)department paediatrics adolescent medicine, princess margaret hospital,
hong kong.

aim: study aims analyze incidence, clinical features, investigation
findings treatment outcomes anti-n-methyl-d-aspartate receptor
encephalitis children hong kong.
method: retrospective study carried paediatric patients diagnosed
with anti-nmdar encephalitis hong kong january 2009 december 2015.
results: fifteen patients (67% female, 93% chinese) identified seven
years estimated incidence hong kong 2.2/million children per year 
(95% ci 1.2-3.6). median age presentation 12 years (range 1-17 years).
the common symptom groups observed abnormal psychiatric behavior or
cognitive dysfunction (14/15, 93%) seizures (14/15, 93%), followed speech 
dysfunction (13/15, 87%), movement disorders (12/15, 80%), decreased level of
consciousness (10/15, 67%) autonomic dysfunction central hypoventilation
(5/15, 33%). median number symptom groups developed patient 5 
(range 3-6). patients treated intravenous immunoglobulin and/or
steroids. three patients (20%) severe presentation required additional 
plasmapheresis rituximab. outcome assessable 14 patients. among 
eleven patients received intravenous immunoglobulin and/or steroids,
nine patients (82%) achieved full recovery. one patient (9%) residual
behavioral problem, another one (9%) developed anti-nmdar encephalitis 
after herpes simplex virus encephalitis complicated dyskinetic cerebral 
palsy epilepsy. among three patients required plasmapheresis and
rituximab, one (33%) full recovery two (66%) substantial recovery.
the median duration follow 20.5 months (range 3-84 months).
conclusion: anti-nmdar encephalitis acquired, severe, potentially
treatable disorder. ethnicity may play role incidence anti-nmdar
encephalitis provided local incidence majority patients
being chinese. diagnosis anti-nmdar encephalitis considered in
children presenting constellation symptoms including psychiatric and
neurological manifestations. patients may respond first line immunotherapy.
for not, second line therapy indicated order achieve a
better outcome.

copyright © 2018 japanese society child neurology. published elsevier
b.v. rights reserved.

doi: 10.1016/j.braindev.2018.02.005 
pmid: 29599011  [indexed medline]

